Antibody Response Against SARS-CoV-2 in Dialysis Patients During COVID-19

• Conditions: COVID; Terminal Renal Insufficiency

• Registration Number: NCT04367714
• Lead Sponsor: Region MidtJylland Denmark

Brief Summary

Determination of IgM and IgG antibodies against SARS-CoV-2 in dialysis patients by continous monitoring in the period from March 2020 to december 2020

Detailed Description

Blood samples are collected every 14 days

Study Timeline

• Study Start: 2020-03-15
• Study First Submitted: 2020-04-27
• Study First Submitted QC: 2020-04-27
• Study First Posted: 2020-04-29
• Status Verified: 2020-12
• Last Update Submitted: 2020-12-29
• Last Update Posted: 2020-12-30
• Primary Completion: 2021-12-01
• Study Completion: 2021-12-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• Dialysis

Exclusion Criteria

• Not willing to give consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
AAntibody response	1 year	IgM and IgG against SARS-CoV-2

Trial Locations

Locations (1)

Godstrup Hospital; 🇩🇰 Herning, Denmark